3:45 PM - 4:00 PM (EDT), Tuesday, June 6, 2023 ・ Session Room 104C
Baseimmune is a discovery stage biotech company developing future-proof antigens. Based on proprietary deep learning technology that models pathogen evolution and immune responses to generate artificial antigens compatible with any delivery systems such as mRNA and viral vectors. Founded by a team that pioneered computational approaches to design vaccines against various infectious diseases at the Jenner Institute University of Oxford. This work led in two vaccines in clinical trials with multi-strain cross-reactivity. Baseimmune is now leveraging its next-generation technology to generate mutation-proof vaccine antigens which can be applied to complex, rapidly mutating pathogens and emerging pathogens. Baseimmune is focused on discovery and pre-clinical development of a number of universal human and veterinary vaccines including Malaria, Coronavirus and African Swine Fever and is looking for out-licensing and co-development partnerships.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
United Kingdom
Year Founded:
Main Therapeutic Focus:
Infectious Diseases
Lead Product in Development:
Universal Coronavirus vaccine
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Chief Scientific Officer